Literature DB >> 16732370

A novel fibrinogen Bbeta chain frameshift mutation in a patient with severe congenital hypofibrinogenaemia.

Xiucai Xu1, Jingsheng Wu, Zhimin Zhai, Rongfu Zhou, Xuefeng Wang, Hongli Wang, Kaiyang Ding, Zimin Sun, Heyu Ni.   

Abstract

Congenital afibrinogenemia and severe hypofibrinogenemia are severe bleeding disorders characterized by either undetectable or very low levels of fibrinogen in patients' plasma and platelets. A majority of the reported cases are caused by mutations in the fibrinogen Aalpha chain. In this study, we identified a genetic defect in the fibrinogen Bbeta-chain (FGB) underlying severe hypofibrinogenemia. The propositus frequently displayed bleeding episodes with a prolonged blood-clotting time (thrombin time > 180 s, activated partial thromboplastin time > 300 s, prothrombin time > 120 s) and had a very low level of plasma fibrinogen (1.7-1.8 mg/dl). His parents had a consanguineous marriage, and their functional and immunological fibrinogen was approximately half of the normal level. The platelet fibrinogen level of the propositus could not be detected by western blotting, and his platelet aggregation was severely impaired. DNA screening of the whole fibrinogen gene revealed a homozygous GGGG-->GGG mutation at nucleotide 7,969-7,972 in his FGB gene. The propositus' parents are both heterozygous for this mutation. This mutation contributes to Gly419-->Val, and the 419-434 codons are frame shifted, and a stop codon is formed at codon 435. The predicted truncated Bbeta-chain is 27 amino acids shorter than the normal Bbeta-chain and a central beta-strand in the globular betaC domain is absent, which may lead to destabilization of the entire beta-domain. To the best of our knowledge, this is the first report of such a mutation which is associated with severe hypofibrinogenemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16732370     DOI: 10.1160/TH06-01-0020

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Plasma fibronectin supports hemostasis and regulates thrombosis.

Authors:  Yiming Wang; Adili Reheman; Christopher M Spring; Jalil Kalantari; Alexandra H Marshall; Alisa S Wolberg; Peter L Gross; Jeffrey I Weitz; Margaret L Rand; Deane F Mosher; John Freedman; Heyu Ni
Journal:  J Clin Invest       Date:  2014-09-02       Impact factor: 14.808

Review 2.  Fibronectin maintains the balance between hemostasis and thrombosis.

Authors:  Yiming Wang; Heyu Ni
Journal:  Cell Mol Life Sci       Date:  2016-04-21       Impact factor: 9.261

3.  All-trans-retinoic acid ameliorated high fat diet-induced atherosclerosis in rabbits by inhibiting platelet activation and inflammation.

Authors:  Birong Zhou; Ying Pan; Zeping Hu; Xiaobian Wang; Jianxiong Han; Qing Zhou; Zhimin Zhai; Yuan Wang
Journal:  J Biomed Biotechnol       Date:  2012-03-01

4.  Platelets and platelet alloantigens: Lessons from human patients and animal models of fetal and neonatal alloimmune thrombocytopenia.

Authors:  Brian Vadasz; Pingguo Chen; Issaka Yougbaré; Darko Zdravic; June Li; Conglei Li; Naadiya Carrim; Heyu Ni
Journal:  Genes Dis       Date:  2015-06-01

5.  Dysregulated coagulation associated with hypofibrinogenaemia and plasma hypercoagulability: implications for identifying coagulopathic mechanisms in humans.

Authors:  Rita Marchi; Bethany L Walton; Colleen S McGary; Feng-Chang Lin; Alice D Ma; Rafal Pawlinski; Nigel Mackman; Robert A Campbell; Jorge Di Paola; Alisa S Wolberg
Journal:  Thromb Haemost       Date:  2012-07-26       Impact factor: 5.249

6.  Platelets in hemostasis and thrombosis: Novel mechanisms of fibrinogen-independent platelet aggregation and fibronectin-mediated protein wave of hemostasis.

Authors:  Yan Hou; Naadiya Carrim; Yiming Wang; Reid C Gallant; Alexandra Marshall; Heyu Ni
Journal:  J Biomed Res       Date:  2015-10-30

Review 7.  Crosstalk Between Platelets and Microbial Pathogens.

Authors:  Conglei Li; June Li; Heyu Ni
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.